Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial

Published:2021-09 Issue:9 Volume:8 Page:e648-e657
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Zoellner Anna-Katharina,Unterhalt Michael,Stilgenbauer Stephan,Hübel Kai,Thieblemont Catherine,Metzner Bernd,Topp Max,Truemper Lorenz,Schmidt Christian,Bouabdallah Kamal,Krauter Jürgen,Lenz Georg,Dürig Jan,Vergote Vibeke,Schäfer-Eckart Kerstin,André Marc,Kluin-Nelemans Hanneke C,van Hoof Achiel,Klapper Wolfram,Hiddemann Wolfgang,Dreyling Martin,Hoster Eva

Funder

Commission of the European Communities

Bundesministerium fur Bildung und Forschung Dienststelle Bonn

Stiftung Deutsche Krebshilfe

Publisher

Elsevier BV

Subject

Hematology

Reference23 articles.

1. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

2. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

3. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma;Le Gouill;N Engl J Med,2017